Thu, May 1, 10:18 AM (18 days ago)
**Glaukos Corporation (GKOS) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** $106.7 million, up 25% YoY. - **Gross Margin:** 77%, slightly up from 76% in Q1 2024. - **Operating Expenses:** $103.0 million, slightly down from $104.4 million in Q1 2024. - **Net Loss:** $18.1 million, down 56% from $40.8 million in Q1 2024. - **Cash Position:** $298.7 million in cash, cash equivalents, and short-term investments. **Key Metrics:** - **Net Sales Growth:** Driven by iDose TR sales and increased iStent family product volumes. - **Operating Expenses:** Increased SG&A and R&D expenses due to commercial infrastructure growth and clinical studies. - **Cash Flow:** Negative operating cash flow of $18.5 million, primarily due to net loss and changes in working capital. **Trends and Uncertainties:** - **Market Conditions:** Global economic conditions and supply chain disruptions may impact operations. - **Reimbursement:** Ongoing efforts to establish consistent reimbursement for iDose TR. - **Competitive Landscape:** Increased competition and potential new entrants may affect market share. **Future Operations Impact:** - **Growth Strategy:** Focus on expanding global sales, marketing, and R&D efforts. - **Capital Expenditures:** Higher capital expenditures expected in 2025 for manufacturing facilities and R&D equipment. - **Liquidity:** Sufficient cash to meet ongoing operations, capital expenditures, and other obligations for at least the next 12 months. **Conclusion:** Glaukos Corporation showed improved financial performance in Q1 2025 with increased revenue and reduced net loss. However, the company faces challenges related to market conditions, reimbursement, and competition. The focus remains on growth, innovation, and maintaining a strong cash position to support future operations.